- Home
- KIND vs INAB Comparison
KIND vs INAB Comparison
Compare KIND & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIND
- INAB
- Stock Information
- Founded
- KIND 2011
- INAB 2016
- Country
- KIND United States
- INAB United States
- Employees
- KIND N/A
- INAB N/A
- Industry
- KIND Computer Software: Programming Data Processing
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- KIND Technology
- INAB Health Care
- Exchange
- KIND Nasdaq
- INAB Nasdaq
- Market Cap
- KIND 974.5M
- INAB 24.0M
- IPO Year
- KIND N/A
- INAB 2021
- Fundamental
- Price
- KIND $2.42
- INAB $0.25
- Analyst Decision
- KIND Hold
- INAB Strong Buy
- Analyst Count
- KIND 2
- INAB 3
- Target Price
- KIND $2.75
- INAB $7.75
- AVG Volume (30 Days)
- KIND 2.3M
- INAB 727.4K
- Earning Date
- KIND 11-06-2024
- INAB 11-12-2024
- Dividend Yield
- KIND N/A
- INAB N/A
- EPS Growth
- KIND N/A
- INAB N/A
- EPS
- KIND N/A
- INAB N/A
- Revenue
- KIND $237,605,000.00
- INAB N/A
- Revenue This Year
- KIND $14.90
- INAB N/A
- Revenue Next Year
- KIND $14.61
- INAB N/A
- P/E Ratio
- KIND N/A
- INAB N/A
- Revenue Growth
- KIND 9.99
- INAB N/A
- 52 Week Low
- KIND $1.32
- INAB $0.22
- 52 Week High
- KIND $3.00
- INAB $1.93
- Technical
- Relative Strength Index (RSI)
- KIND 41.53
- INAB 39.26
- Support Level
- KIND $2.26
- INAB $0.28
- Resistance Level
- KIND $2.68
- INAB $0.32
- Average True Range (ATR)
- KIND 0.13
- INAB 0.03
- MACD
- KIND -0.03
- INAB -0.01
- Stochastic Oscillator
- KIND 16.04
- INAB 13.73
About KIND Nextdoor Holdings Inc.
Nextdoor Holdings Inc is the platform to connect to the neighborhoods. The purpose is to cultivate a kinder world where everyone has a neighborhood. Neighbors around the world turn to Nextdoor daily to receive trusted information, give and get help, get things done, and build real-world connections with nearby neighbors, businesses, and public services.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.